Bausch: Positive Topline in Phase 2 Study Evaluating Amiselimod (an S1P antagonist) in Ulcerative Colitis

 Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") today announced positive topline results from the Company's Phase 2 study evaluating Amiselimod, an investigative S1P antagonist, for the treatment of ulcerative colitis (UC).

https://www.biospace.com/article/releases/bausch-health-announces-positive-topline-results-from-global-phase-2-study-evaluating-amiselimod-an-s1p-antagonist-to-treat-ulcerative-colitis/